Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case

Journal of Viral Hepatitis

Volumn 23, Issue 10, 2016, Pages 767-779

  Deuffic Burban, S ^a,b,c   Obach, D ^a,b   Canva, V ^d   Pol, S ^e,f   Roudot Thoraval, F ^g   Dhumeaux, D ^g   Mathurin, P ^c,d   Yazdanpanah, Y ^a,b,h  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIV LILLE   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e Institut Cochin   (France)

^f INSTITUT COCHIN   (France)

^g HENRI MONDOR HOSPITAL   (France)

^h BICHAT HOSPITAL   (France)

Author keywords

budget impact analysis; chronic hepatitis C; cohort Markov model; cost effectiveness analysis; interferon free direct acting antiviral agents

Indexed keywords

ANTIVIRUS AGENT; INTERFERON FREE DIRECT ACTING ANTIVIRAL AGENT; PEGINTERFERON ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC HEPATITIS C; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FRANCE; GENOTYPE; HEALTH CARE COST; HUMAN; LIVER FIBROSIS; MARKOV CHAIN; PRIORITY JOURNAL; QUALITY OF LIFE; SENSITIVITY ANALYSIS; TREATMENT RESPONSE;

EID: 84987850048     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12546     Document Type: Article

References (40)

1. Welsch C, Jesudian A, Zeuzem S, Jacobson I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 2012; 61(Suppl. 1): i36–i46.
2. Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368(20): 1878–1887.
3. Sulkowski MS, Gardiner DF, Rodriguez-Torres M et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370(3): 211–221.
4. Lawitz E, Lalezari JP, Hassanein T et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13(5): 401–408.
5. Lawitz E, Sulkowski MS, Ghalib R et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384(9956): 1756–1765.
6. Zeuzem S, Dusheiko GM, Salupere R et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370(21): 1993–2001.
7. Jacobson IM, Gordon SC, Kowdley KV et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368(20): 1867–1877.
8. Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370(16): 1483–1493.
9. Afdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370(20): 1889–1898.
10. Deuffic-Burban S, Schwarzinger M, Obach D et al. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). J Hepatol 2014; 61(1): 7–14.
11. Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 2014; 60: 530–537.
12. Leidner AJ, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology 2015; 61(6): 1860–1869.
13. Aasld-Idsa HCV. Guidance panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62(3): 932–954.
14. European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63(1): 199–236.
15. Association Française pour l'Etude du Foie (AFEF). Recommandations AFEF sur la prise en charge des hépatites virales C. Juin 2015.
16. Prise en charge des personnes infectées par les virus de l'hépatite B ou de l'hépatite C. Rapport de recommandations 2014. Sous la direction du Pr Daniel Dhumeaux et sous l'égide de l'ANRS et de l'AFEF.
17. Association Française pour l'Etude du Foie (AFEF). Prise de position de l'Association Française pour l'Etude du Foie (AFEF) sur les trithérapies (Peg-IFN + ribavirine + inhibiteur de protéase) dans la prise en charge des malades atteints d'hépatite chronique C. Paris, 2011.
18. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol 2014; 61(2): 373–395.
19. Deuffic-Burban S, Mathurin P, Pol S et al. Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis. Gut 2012; 61(2): 290–296.
20. van der Meer AJ, Veldt BJ, Feld JJ et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308(24): 2584–2593.
21. Cossais S, Schwarzinger M, Deuffic-Burban S et al. EQ-5D utility index in french patients with chronic hepatitis C (CHC) infection: severe comorbidities and perceived progression of CHC infection matter more than actual liver disease stage. J Hepatol 2015; 62(Suppl. 2): S605.
22. Chevalier J, de Pouvourville G. Valuing EQ-5D using time trade-off in France. Eur J Health Econ 2013; 14(1): 57–66.
23. Pol S, Chevalier J, Branchoux S, Perry R, Milligan G, Gaudin A-F. Health related quality of life and utility values in chronic hepatitis C patients: a cross-sectional study in France, the UK and Germany (P0747). J Hepatol 2015; 62(Suppl. 2): S606.
24. Siebert U, Sroczynski G, Wasem J et al. Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany. Eur J Health Econ 2005; 6: 112–123.
25. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
26. HAS Haute Autorité de Santé. Guide méthodologique : Choix méthodologiques pour l'évaluation économique á la HAS. Octobre 2011: Haute Autorité de Santé, 2011: 83.
27. WHO. Making choices in health: WHO guide to cost-effectiveness analysis. In: Tan-Torres Edejer T, Baltussen RM, Adams T, Hutubessy R, Acharya A, Evans DB, Evans CJL eds. http://www.who.int/choice/publications/p_2003_generalised_cea.pdf Geneva: WHO, 2003.
28. The World Bank. Data. GDP per capita, PPP (current international $).
29. Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Dhersin J-S, Yazdanpanah Y. Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. Hepatology 2016; 63(4): 1090–1101.
30. Gane EJ, Hyland RH, Svarovskaia ES et al. High Efficacy of LDV/SOF Regimens for 12 Weeks for Patients With HCV Genotype 3 or 6 Infection. Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA, Nov 7–11, 2014.
31. Najafzadeh M, Andersson K, Shrank WH et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015; 162(6): 407–419.
32. Sloan CE, Champenois K, Choisy P et al. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS 2012; 26(1): 45–56.
33. Supervie V, Costagliola D. The spectrum of engagement in HIV care in France: strengths and gaps. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA: March 2013. Abstract #1030.
34. Ameli. Base des Médicaments et Informations Tarifaires. 2015.
35. Legifrance JO 20 Novembre 2014. Avis relatif aux prix de spécialités pharmaceutiques publiés en application des articles L 162-16-5 du code de la sécurité sociale: Ministère des Affaires Sociales, de la Santé et des Droits des femmes, 2014.
36. Legifrance JO 17 Juin 2015. Avis relatif aux prix de spécialités pharmaceutiques publiés en application de l'article L 162-16-5 du code de la sécurité sociale: Ministère des Affaires Sociales, de la Santé et des Droits des femmes, 2015.
37. Legifrance JO 21 Mai 2015. Avis relatif aux prix de spécialités pharmaceutiques publiés en application des articles L 162-16-5 et L 162-16-6 du code de la sécurité sociale: Ministère des Affaires Sociales, de la Santé et des Droits des femmes, 2015.
38. Legifrance JO 28 Août 2015. Avis relatif aux prix de spécialités pharmaceutiques publiés en application des articles L 162-16-5 du code de la sécurité sociale: Ministère des Affaires Sociales, de la Santé et des Droits des femmes, 2015.
39. Agence Technique de l'Information sur l'Hospitalisation. Le programme de médicalisation des systèmes d'information en médecine, chirurgie, obstétrique et odontologie.
40. Caisse Nationale de Santé. Liste positive des médicaments valable au 1er juillet 2015. 2015.